胆管癌治疗药物培米替尼说明书

Cholangiocarcinoma Treatment Drug Instructions

Generic name: pemigatinib

Product name: pemazyre

Full names: pemetinib, pemetinib, pemigatinib, pemazyre

Pemetinib Indication: Adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.

[Pemetinib usage and dosage]

Before initiating treatment with pemetinib, confirm the presence of FGFR2 fusions or rearrangements.

The recommended dose is 13.5 mg orally daily for 14 days, followed by 7 days off in a 21-day cycle. Continue treatment until disease progression or unacceptable toxicity.

Swallow the tablets whole, with or without food.

[Side Effects of Pemetinib] The most common side effects (incidence ≥20%) are hyperphosphatemia, alopecia, diarrhea, nail toxicity, fatigue, dyspepsia, nausea, constipation, stomatitis, dry eye, dry mouth, loss of appetite, vomiting, joint pain, abdominal pain, hypophosphatemia, back pain, and dry skin.

[Precautions for pemetinib]

1. Pemetinib can cause retinal pigment epithelial detachment. Ophthalmological examinations, including optical coherence tomography (OCT), were performed before the start of treatment, every 2 months for the first 6 months of treatment and every 3 months thereafter, and at any time visual symptoms emerged urgently.

  2. Hyperphosphatemia: Increased phosphate levels are the pharmacodynamic effect of pemetinib. Monitor and prevent hyperphosphatemia, reduce dose or

3. Permanently terminate treatment based on the duration and severity of hyperphosphatemia.

4. Embryo-fetal toxicity: Can cause fetal harm. Inform patients of the potential risk to the fetus of reproductive potential and to use effective contraception.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: